All > Diffuse Large B Cell Lymphoma > Lymphoma

Pembrolizumab for Non-Hodgkin's Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Non-Hodgkin's Lymphoma+1 MorePembrolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new immunotherapy drug for people with a certain type of lymphoma that has come back or didn't respond to other treatment.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Pembrolizumab
1
Pembrolizumab
1
Pembrolizumab

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 5 years

2 years
Duration of response (DOR) to pembrolizumab treatment
Overall response rate (ORR) to pembrolizumab treatment compared to historical controls.
Progression-free survival (PFS)
5 years
Overall survival (OS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Pembrolizumab
1
Pembrolizumab
2
Pembrolizumab

Side Effects for

Pembrolizumab Second Course
100%Parkinsonism
100%Urinary tract infection
100%Inappropriate antidiuretic hormone secretion
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab Second Course ARM group. Side effects include: Parkinsonism with 100%, Urinary tract infection with 100%, Inappropriate antidiuretic hormone secretion with 100%.

Trial Design

1 Treatment Group

Pembrolizumab Treatment
1 of 1

Experimental Treatment

29 Total Participants · 1 Treatment Group

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2

Pembrolizumab Treatment
Drug
Experimental Group · 1 Intervention: Pembrolizumab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

University of ChicagoLead Sponsor
927 Previous Clinical Trials
753,983 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,681 Previous Clinical Trials
4,957,422 Total Patients Enrolled
Justin Kline, MDPrincipal InvestigatorUniversity of Chicago
2 Previous Clinical Trials
77 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Participants must have archived biopsy material (ideally to be performed shortly before enrollment at the time of most recent relapse) for PD-L1 FISH and correlative studies.
A positive PD-L1 FISH assay in lymphoma cells indicates a PD-L1 gene alteration.
You provide informed consent for the trial.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top